Lifeboat Foundation

It would be the first new treatment in 20 years for UTIs, which affect more than half of women at least sometime in their life, according to data compiled by the Department of Health and Human Services.

Called Gepotidacin, the antibiotic’s trial has halted enrollment early due to excellent effectiveness and safety results thus far, drugmaker GSK announced in a press release Thursday. GSK will seek approval and peer-reviewed publication early next year.

There is a need for new antibiotics such as this due to increasing antibiotic resistance. Antibiotic resistance to bacteria has become so prevalent that the World Health Organization recently began publishing a list of bacteria that pose the greatest public health threats.

Cancer research – and its impact on patient care – has made some significant strides in just the last 10 years. For example, the availability and affordability of sequencing genetic information has improved greatly – meaning researchers and doctors are now better able to get information about a person’s risk for certain cancers as well as what drugs might work best for cancer patients. Another major leap forward came with the approval of vaccines that help prevent infections from the human papilloma virus (HPV) that cause cervical cancers. Many other advances have occurred in the areas of targeted therapy, immunotherapy, and cancer screening technology.

Still, cancer remains a massive health problem that researchers across the United States and elsewhere are working tirelessly to solve. Many experts are hopeful that they can build on decades of learning and recent advances to move even more rapidly toward reducing the cancer burden.

We invited 10 American Cancer Society Research Professors to share their perspectives and predictions for how cancer research will evolve over the next 10 years – and what this might mean for patients. These 10 experts are among the very best in their field; the Society’s Research Professor grants are awards that go to a select group – researchers and doctors who have made seminal contributions that have changed the direction of basic, clinical, psychosocial, behavioral, health policy or epidemiologic cancer research.

Summary of the study.

On December 6–7, 2022, the Buck Institute for Research on Aging will be hosting the Longevity Summit 2022. Lifespan.io is pleased to announce that we are an official media partner for this upcoming conference.

The Summit will see many of the leading experts in the field coming together in the grounds of the architecturally distinct Buck Institute. It is being framed as a peer-to-peer learning experience aiming to unite longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations.

Here’s what the organizers had to say about the event:

The lone volunteer in a unique study involving a gene-editing technique has died, and those behind the trial are now trying to figure out what killed him.

Terry Horgan, a 27-year-old who had Duchenne muscular dystrophy, died last month, according to Cure Rare Disease, a Connecticut-based nonprofit founded by his brother, Rich, to try and save him from the fatal condition.

Although little is known about how he died, his death occurred during one of the first studies to test a gene editing treatment built for one person. It’s raising questions about the overall prospect of such therapies, which have buoyed hopes among many families facing rare and devastating diseases.

A major hallmark of Parkinson’s disease is the loss of dopamine-producing neurons in the brain, which in turn causes patients to lose motor control abilities. NYSCF – Robertson Stem Cell Investigator Alumna Malin Parmar, PhD, of Lund University, has spent a decade developing a cell therapy to replace these cells, and this revolutionary treatment (called ‘STEM-PD’) has just received approval for a Phase I/IIa clinical trial in Sweden.

“We are excited and looking forward to this clinical study of STEM-PD, hoping that it could potentially help reduce the significant burden of Parkinson’s disease. This has been a massive team effort for over a decade, and the regulatory approval is a major and important milestone,” said Dr. Parmar, who is a Professor of Developmental and Regenerative Neurobiology at Lund, in a statement.

Dr. Parmar’s innovative work towards a Parkinson’s cell therapy earned her the NYSCF – Robertson Stem Cell Investigator Award in 2016, which provided support for her lab’s research until 2021, including her work on STEM-PD.

The controversial scientist freed this year from jail for illegal medical practices has relocated to Beijing for his proposed US$7.2 million project.

Regenerative medicine company Frequency Therapeutics is developing new drugs that activate our innate abilities to restore function and reverse degenerative diseases. The company is working on small molecules that selectively activate progenitor cells already present within our bodies to create healthy, functional tissues. Frequency’s initial focus is on hearing loss and multiple sclerosis, and the company has just completed enrolment of a Phase 2b trial in adults with acquired sensorineural hearing loss (SNHL).

Longevity. Technology: Frequency is focused on progenitor cells, which are like stem cells but can only make cells that belong to the same tissue or organ. While progenitor cells remain active in some of our organs and tissues, they can become dormant in others. Frequency’s small molecules are designed to selectively target and induce dormant progenitor cells to create specific cell types to restore tissue structure and function. We caught up with Frequency’s Chief Scientific Officer Dr Chris Loose to learn more.

Nasdaq-listed Frequency was founded in 2014, licensing technology developed by professors Robert Langer from MIT and Jeffrey Karp from Harvard Medical School.

Dr talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research.

We were lucky enough to attend the Longevity Investors Conference last month; this key event attracts those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. To put it succinctly, as MIT Tech Review did recently, LIC “brings academic scientists and biotech companies together with deep-pocketed investors. We’re talking millionaires and billionaires.”

Continue reading “Tobias Reichmuth — the longevity market starts now” »